Alligator Bioscience AB: Interim report January–June 2021
Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the company have been surpassed already. During this short time, I have been ascertained that Alligator has a strong pipeline that builds on a powerful technology platform.” Søren Bregenholt, CEO Alligator Bioscience ABSIGNIFICANT EVENTS APRIL-JUNE 2021 Pipeline: · An article prepared by scientists at Alligator, on CD40 agonistic antibodies was published in Expert Opinion on Biological Therapy. · ATOR-1017 is the first monoclonal 4-1BB